



(86) **Date de dépôt PCT/PCT Filing Date:** 2016/02/11
(87) **Date publication PCT/PCT Publication Date:** 2016/08/18
(45) **Date de délivrance/Issue Date:** 2019/04/30
(85) **Entrée phase nationale/National Entry:** 2017/06/30
(86) **N° demande PCT/PCT Application No.:** US 2016/017599
(87) **N° publication PCT/PCT Publication No.:** 2016/130837
(30) **Priorités/Priorities:** 2015/02/11 (US62/114,998);
2015/11/04 (US14/932,840)

(51) **Cl.Int./Int.Cl. C09D 5/14** (2006.01),
A61L 2/16 (2006.01)
(72) **Inventeurs/Inventors:**
MOROS, DANIEL, US;
GROSSMAN, CRAIG, US
(73) **Propriétaire/Owner:**
ALLIED BIOSCIENCE, INC., US
(74) **Agent:** GOWLING WLG (CANADA) LLP

(54) **Titre : REVETEMENT ANTI-MICROBIEN ET PROCEDE DE FORMATION DE CELUI-CI**
(54) **Title: ANTI-MICROBIAL COATING AND METHOD TO FORM SAME**

(57) **Abrégé/Abstract:**

An anti-microbial coating formulation consisting essentially of triethanolamine and a silane.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 August 2016 (18.08.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/130837 A1

(51) International Patent Classification:

C09D 5/14 (2006.01) *A01N 55/00* (2006.01)
A01N 29/00 (2006.01) *A01N 59/16* (2006.01)
A01N 33/04 (2006.01) *A61L 2/00* (2006.01)

(21) International Application Number:

PCT/US2016/017599

(22) International Filing Date:

11 February 2016 (11.02.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/114,998 11 February 2015 (11.02.2015) US
14/932,840 4 November 2015 (04.11.2015) US

(71) Applicant: **ALLIED BIOSCIENCE, INC.** [US/US]; 100
Crescent Court, Suite 450, Dallas, TX 75201 (US).

(72) Inventors: **MOROS, Daniel**; 100 Crescent Court, Suite
450, Dallas, TX 75201 (US). **GROSSMAN, Craig**; 100
Crescent Court, Suite 450, Dallas, TX 75201 (US).

(74) Agent: **REGELMAN, Dale, F.**; Quarles & Brady LLP,
One South Church Avenue, Suite 1700, Tucson, AZ
85701-1621 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ANTI-MICROBIAL COATING AND METHOD TO FORM SAME

(57) Abstract: An anti-microbial coating formulation consisting essentially of triethanolamine and a silane.



WO 2016/130837 A1

ANTI-MICROBIAL COATING AND METHOD TO FORM SAME

Field Of The Invention

[0001] Embodiments generally relate an anti-microbial coating composition, and a method using that coating composition. In certain embodiments, the coating composition comprises a photocatalyst. In certain embodiments, the photocatalyst comprises a titanyl-oxide moiety. In certain embodiments, the coating composition comprises a silane.

Brief Description Of The Drawings

[0002] The invention will be better understood from a reading of the following detailed description taken in conjunction with the drawings in which like reference designators are used to designate like elements, and in which:

[0003] FIG. 1 graphically shows the number of hospital acquired *C-difficile* infections in the Glendale Memorial Hospital ICU from January 2012 through February 2014;

[0004] FIG. 2 graphically shows the number of hospital acquired *C-difficile* infections at the Glendale Memorial Hospital (excluding ICU) from January 2012 through February 2014;

[0005] FIG. 3 shows anti-microbial efficacy data zero (0) hours after inoculation of the treated test coupons;

[0006] FIG. 4 recite anti-microbial efficacy data four (4) hours after inoculation of the treated test coupon which includes data for ABS-G2020 AND ABS-G2030 treated Formica coupons;

[0007] FIG. 5 recite anti-microbial efficacy data four (4) hours after inoculation of the treated test coupon which includes data for ABS-G2020 AND ABS-G2030 treated stain less steel coupons;

[0008] FIG. 6 recite surface time-kill study evaluating two coating formulations against murine norovirus (6) hours contact time data;

- [0009] FIG. 7 recites CFU/mL data for each of the three coating formulations, wherein each formulation did not include one or more titanium-oxide moieties;
- [0010] FIG. 8 recites Log Reduction data for the three formulations evaluated, wherein each formulation did not include one or more titanium-oxide moieties;
- [0011] FIG. 9 recites Percent Reduction data for the three formulations utilized, wherein each formulation did not include one or more titanium-oxide moieties;
- [0012] FIG. 10 recite anti-microbial efficacy data for certain electrostatic spray embodiments;
- [0013] FIG. 11 recite anti-microbial efficacy data for certain electrostatic spray embodiments;
- [0014] FIG. 12 recite anti-microbial efficacy data for certain electrostatic spray embodiments;
- [0015] FIG. 13 recite anti-microbial efficacy data for certain non-electrostatic spray embodiments;
- [0016] FIG. 14 recite anti-microbial efficacy data for certain non-electrostatic spray embodiments; and
- [0017] FIG. 15 recite anti-microbial efficacy data for certain non-electrostatic spray embodiments.

Detailed Description Of The Preferred Embodiments


[0018] This invention is described in preferred embodiments in the following description with reference to the Figures, in which like numbers represent the same or similar elements. Reference throughout this specification to “one embodiment,” “an embodiment,” or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.

[00019] The described features, structures, or characteristics of the invention may be combined in any suitable manner in one or more embodiments. In the following description, numerous specific details are recited to provide a thorough understanding of embodiments of the invention. One skilled in the relevant art will recognize, however, that the invention may be practiced without one or more of the specific details, or with other methods, components, materials, and so forth. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the invention.

[00020] In certain embodiments of Inventors' composition and method, a coating is formed on a surface, where that coating comprises a plurality of silicon - oxygen bonds. In certain embodiments of Inventors' composition and method, a coating is formed on a surface, where that coating comprises a plurality of titanium - oxygen bonds in combination with a plurality of silicon-oxygen bonds.

[00021] In certain embodiments, a coating comprising a plurality of titanyl-oxide bonds in combination with a plurality of silicon-oxygen bonds is formed by disposing on a surface a silane in combination with one or more compounds comprising one or more titanyl-oxygen bonds. In certain embodiments, a coating comprising a plurality of titanyl-oxide bonds in combination with a plurality of silicon-oxygen bonds is formed by first disposing one or more compounds comprising one or more titanyl-oxygen bonds on the surface, and by disposing a silane onto the surface and over the one or more compounds comprising one or more titanyl-oxygen bonds. In certain embodiments, a coating comprising a plurality of titanyl-oxide bonds in combination with a plurality of silicon-oxygen bonds is formed by simultaneously disposing one or more compounds comprising one or more titanyl-oxygen bonds and a silane onto the surface.


[00022] In certain embodiments, Inventors' silane comprises compound 1.



1

[00023] In certain embodiments, R1 is selected from the group consisting of OH and O-Alkyl. In certain embodiments, R2 is selected from the group consisting of OH and O-Alkyl. In certain embodiments, R3 is selected from the group consisting of OH and O-Alkyl. In certain embodiments, R4 is selected from the group consisting of OH, O-Alkyl, Alkyl, substituted Alkyl including γ -chloro-propyl, γ -amino-propyl, and quarternary ammonium salt-substituted Alkyl.


[00024] In certain embodiments, Inventors' silane comprises a trihydroxy silane 2.



2

[00025] In certain embodiments, Inventors' silane comprises a silanetriol 2, wherein R4 is alkyl. In other embodiments, Inventors' silane comprises a silanetriol 2, wherein R4 is alkyl with an amino moiety. In yet other embodiments, Inventors' silane comprises a silanetriol 2, wherein R4 is alkyl with a chlorine substituent. In still other embodiments, Inventors' silane comprises a silanetriol 2, wherein R4 is alkyl with a quarternary ammonium group.

[00026] A silsesquioxane is an organosilicon compound 3 where Si represents the element silicon and O represents the element oxygen.



3

In certain embodiments, after application of Inventors' silane 1 or 2 to either a hard surface, i.e. wall, door, table, and the like, or a soft surface, i.e. bedding, draperies, furniture cushions, and the like, a resulting coating disposed on the hard surface / soft surface comprising a plurality of silsesquioxane structures. In certain embodiments, after application of Inventors' silane 1 or 2, in combination with one or more compounds comprising a titanyl-oxygen moiety, to either a hard surface, i.e. wall, door, table, and the like, or a soft surface, i.e. bedding, draperies, furniture cushions, and the like, a resulting coating disposed on the hard surface / soft surface comprises a plurality of silsesquioxane structures 3 in combination with plurality of titanyl-oxide structures.

[00027] Oxidation is a loss of electrons or an increase in oxidation state by a molecule, atom or ion. Substances that have the ability to oxidize other substances are said to be oxidative or oxidizing and are known as oxidizing agents, oxidants, or oxidizers. Put another way, the oxidant removes electrons from another substance, and is thus itself reduced. And, because it "accepts" electrons, it is also called an electron acceptor.

[00028] In chemistry, photocatalysis is the acceleration of a photoreaction in the presence of a catalyst. In catalyzed photolysis, light is absorbed by an adsorbed substrate. In photogenerated catalysis, the photocatalytic activity (PCA) depends on the ability of the catalyst to create electron-hole pairs, which generate free radicals (hydroxyl radicals: $\bullet\text{OH}$) able to undergo secondary reactions. Its comprehension has been made possible ever since the discovery of water electrolysis by means of the titanium dioxide.

[00029] Certain titanyl-oxide morphologies exhibit photocatalytic characteristics when exposed to Ultra Violet (UV) light. When exposed to UV light, Inventors' Titanyl-Oxide Moieties create electron-hole pairs which generate free radical (e.g., hydroxyl radicals). The degree of photocatalytic strength varies depending on the type of titanyl-oxide, for example anatase titanium oxide (particle size of about 5 to 30 nanometers) is a stronger photocatalyst than rutile titanium oxide (particle size of about 0.5 to 1 microns).

[00030] In certain embodiments of Inventors' composition and method, a coating is formed on a surface, where that coating comprises a plurality of titanyl-oxide bonds, where that coating is formed by disposing Inventors' Titanyl-Oxide Moieties onto a target surface.


[00031] In certain embodiments of Inventors' composition and method, a coating is formed on a surface, where that coating comprises a plurality of silicon-oxygen bonds, where that coating is formed by disposing Inventors' silane 1 onto the surface.

[00032] In certain embodiments of Inventors' composition and method, a coating is formed on a surface, where that coating comprises a plurality of titanyl-oxide bonds, where that coating is formed by disposing on the surface a mixture of Peroxotitanium acid solution and Peroxo-modified anatase sol (collectively "Titanyl-Oxide Moieties").


[00033] In certain embodiments, Inventors' Titanyl-Oxide Moieties comprises up to about a total of one weight percent loading of the mixture of Peroxotitanium acid solution and Peroxo-modified anatase sol. In certain embodiments, Inventors' Titanyl-Oxide Moieties comprises about 0.5 weight percent Peroxotitanium acid solution in combination with about 0.5 weight percent Peroxo-modified anatase sol.

[00034] A method to prepare both Peroxotitanium acid solution and Peroxo-modified anatase sol is disclosed in Journal of Sol-Gel Science and Technology, September 2001, Volume 22, Issue 1-2, pp 33-40. This publication discloses, *inter alia*, Reaction Scheme 1, shown immediately hereinbelow, which summarizes the synthetic procedure for both Peroxotitanium acid solution and Peroxo-modified anatase sol.

REACTION SCHEME 1




[00035] In the following examples, reference is made to coatings ABS-G2015, ABS-G2020, and ABS-G2030. Coating formulation ABS-G2015 comprises a silicone-containing compound having structure V:



V


[00036] Coating formulation ABS-G2015 further comprises the Titanyl-Oxide Moieties. The order of deposition onto a surface is not critical. In certain embodiments, the silicone-containing compound is first disposed on a surface, and the Titanyl-Oxide Moieties are disposed over that silicone-containing compound. In other embodiments, the Titanyl-Oxide Moieties are first disposed on a surface, and the silicone-containing compound is disposed over that Titanyl-Oxide Moieties - treated surface. In yet other embodiments, the Titanyl-Oxide Moieties and the silicone-containing compound are first pre-mixed, and the resulting mixture is disposed on the surface of the substrate.

[00037] Coating formulation ABS-G2020 comprises a silicone-containing compound having structure VI:



[00038] Coating formulation ABS-G2020 further comprises the Titanyl-oxide Moieties. The order of deposition onto a surface is not critical. In certain embodiments, the silicone-containing compound is first disposed on a surface, and the Titanyl-oxide Moieties are disposed over that silicone-containing compound. In other embodiments, the Titanyl-oxide Moieties are first disposed on a surface, and the silicone-containing compound is disposed over that Titanyl-oxide Moieties-treated surface. In yet other embodiments, the Titanyl-oxide Moieties and the silicone-containing compound are first pre-mixed, and the resulting mixture is disposed on the surface of the substrate.

[00039] Coating formulation ABS-G2030 comprises a silicone-containing compound having structure VII:



VII

[00040] Coating formulation ABS-G2030 further comprises the Titanyl-Oxide Moieties. The order of deposition onto a surface is not critical. In certain embodiments, the silicone-containing compound is first disposed on a surface, and the Titanyl-Oxide Moieties are disposed over that silicone-containing compound. In other embodiments, the Titanyl-Oxide Moieties are first disposed on a surface, and the silicone-containing compound is disposed over that Titanyl-Oxide Moieties-treated surface. In yet other embodiments, the Titanyl-Oxide Moieties and the silicone-containing compound are first pre-mixed, and the resulting mixture is disposed on the surface of the substrate.

[00041] The following Examples are presented to further illustrate to persons skilled in the art how to make and use the invention. These Examples are not intended as limitations, however, upon the scope of the invention.

EXAMPLE 1

[00042] This Example 1 evaluates the anti-microbial efficacy of coatings ABS-G2015, ABS-G020, and ABS G-2030, against Murine Noro Virus. Murine norovirus (MNV) is a species of norovirus affecting mice. Norovirus is the most common cause of viral gastroenteritis in humans. It affects people of all ages. The virus is transmitted by, *inter alia*, aerosolization of the virus and subsequent contamination of surfaces. The virus affects around 267 million people and causes over 200,000 deaths each year; these deaths are usually in less developed countries and in the very young, elderly and immunosuppressed.

[00043] The test coupons of this Example 1 were prepared using the Procedure recited immediately hereinbelow.

Procedure

- [00044] Put on sterile gloves.
- [00045] Prepare the test coupons by wiping them first with Isopropyl Alcohol and allowing to dry.
- [00046] Clean the test coupons with surface cleaner using a microfiber cloth.
- [00047] Hold sprayer about eight (8) inches from surface to be cleaned.
- [00048] Spray on let stand for 1-3 minutes and wipe it off, if the area is extremely dirty allow cleaner to stand longer, or apply a second spray and wipe.
- [00049] Wipe surface with a clean, damp sponge or cloth.
- [00050] Allow surface to completely dry.
- [00051] With gloved hands examine coupons for consistency.
- [00052] Prepare a 10 volume percent solution of the selected silane in Methanol (MeOH) (10 ml silane in 90 ml MeOH).
- [00053] Prepare Triethanolamine as a 10 volume percent solution in MeOH.
- [00054] Combine the triethanolamine solution and the silane solution in a 1:1 ratio on a stir plate at room temperature (ie-100 ml triethanolamine solution added to 100 ml silane solution).

Silane Application

- [00055] Add the silane / triethanolamine solution from [00041] to the applicator container.
- [00056] Fasten the Liquid Hose/Bottle cap assembly tightly on the container.
- [00057] Connect the air hose from compressor to air fitting on the spray applicator.
- [00058] Connect the liquid hose to the liquid fitting on the spray applicator.
- [00059] Plug the power cord into an appropriate receptacle. Turn on the air compressor.
- [00060] Optimal spraying distance is at least 36 to 48 inches away from the target surface.
- [00061] Hold the spray gun at right angles to the target surface and spray.

[00062] Target surface should just barely glisten with the spray. Do not over-saturate the surface.

[00063] Allow target surface to dry, i.e. allow at least 90 weight percent of the methanol liquid carrier to evaporate to give a deposition consisting essentially of the selected silane and triethanolamine. The deposition onto the target surface consists of at least 33 volume percent of the selected silane, at least 33 volume percent of triethanolamine, and up to about 33 volume percent residual methanol carrier liquid.

[00064] Rinse spray gun with distilled water prior to applying Inventors' Titanyl-Oxide Moieties (unless using 2 sprayers, one for each product).

Titanyl-Oxide Moieties Application.

[00065] Add an aqueous mixture of Inventors' Titanyl-Oxide Moieties to the applicator container.

[00066] Fasten the Liquid Hose/Bottle cap assembly tightly on the container.

[00067] Connect the air hose from compressor to air fitting on the spray applicator.

[00068] Connect the liquid hose to the liquid fitting on the spray applicator.

[00069] Plug the power cord into an appropriate receptacle. Turn on the air compressor.

[00070] Optimal spraying distance is at least 36 to 48 inches away from the target surface.

[00071] Hold the spray gun at right angles to the target surface and spray.

[00072] Target surface should just barely glisten with the spray. Do not over-saturate the surface.

[00073] Allow target surface to dry, i.e. allow at least 90 weight percent of the water liquid carrier to evaporate to give a deposition consisting essentially of Inventors' Titanyl-Oxide Moieties. The deposition onto the target surface consists of at least 66 volume percent of Inventors' Titanyl-Oxide Moieties and up to about 33 volume percent residual water carrier liquid.

[00074] Clean the spray gun with distilled water per manufactures' specifications after each day of use.

[00075] FIG. 4 and FIG. 5 recite anti-microbial efficacy data four (4) hours after inoculation of the treated test coupons. FIG. 4 includes data for ABS-G2020 and ABS-G2030 treated Formica coupons. FIG. 5 includes data for ABS-G2020 and ABS-G-2030 treated stain less steel coupons.

[00076] RAW (mouse macrophage) host cells were prepared in 96-well trays 24 hours prior to use in testing.

[00077] On the day of testing, a stock vial of test virus, murine norovirus, was removed from storage at - 80 °C (titer = 5×10^8 TCID 50 units per ml). An organic soil load (heat-inactivated fetal bovine serum) was added to obtain a final concentration of 5%.

[00078] Control (non-coated stainless steel and formica) and coated test carriers [ABS-G2015 (SS); ABS-G2020 (Form); ABS-G2030 (Form); ABS-P2015 (SS)] were placed into sterile Petri dishes (one per dish) using pre-sterilized forceps.

[00079] Viral inocula (0.010 ml) were pipette onto the center of the control and test carriers, and spread over a surface area of $\sim 1\text{-in}^2$ using a sterile, bent pipette tip.

[00080] One set of control carriers (per surface material type) was harvested/neutralized immediately to determine Time Zero counts by placement into sterile stomacher bags containing 3 ml of neutralizing solution (calf serum supplemented with .001% Na-thiosulfate and .001% Na-thioglycollate). The bags were stomached for 120 seconds at high speed to release the viruses from the carriers.

[00081] The remaining control and test carriers were held under ambient conditions for the duration of each of the specified study contact times of 4 hours and 24 hours [placement distance/configuration: ~ 68 inches (~ 1.7 m) below two full-spectrum bulbs, inoculated side facing up towards the lights)]. All carriers were observed to be dried within 10 minutes of inoculation.

[00082] Upon closure of the respective contact times, the control and test carriers were neutralized by placement into sterile stomacher bags containing 3 ml of neutralizing solution, followed by stomaching as previously described.

[00083] At the start and finish of each of the contact times, room temperature, relative humidity, and illuminance (lux) were measured and recorded.

[00084] Control and test carrier eluates were serially diluted (1:10) and plated in replicates of six onto RAW host cells prepared to the appropriate confluency.

[00085] The plates were observed every 24 to 48 hours to visualize viral cytopathic effects (CPE) and cytotoxicity.

[00086] Following a 9-day assay incubation period, the plates were formally scored.

[00087] Log₁₀ and percent reductions were calculated for each of the test coating formulations relative to the timed control virus counts (per surface type). *However, reductions could not be computed for the 24 hour contact time due to insufficient viral recovery from the control carriers.*

[00088] A neutralization validation was performed for each of the test coating formulations (except for ABS-P2015 due to a lack of carriers). One control carrier and one of each test carrier type were placed into stomacher bags containing 3 ml of neutralizer, and processed as previously described. The eluate was serially diluted, and low titer inoculum of the test virus (~3-log₁₀) was added to each of the dilution tubes per control and test carrier suspension. Aliquots (0.1 ml) of the suspensions were then plated in order to assess cytotoxic levels of the neutralized test materials.

EXAMPLE 2

[00089] This Example 2 utilizes the three (3) silanes utilized in coating formulations, namely ABS-G2015, ABS-G2020, and ABS-G2030, but without any Titanyl-Oxide containing compounds. The method of Example 1 from Paragraph [00044] through Paragraph [00064] relating to spray deposition of a silane onto test coupons was utilized in this Example 2. The method of Paragraph [00065] through and including Paragraph [00074] relating to spray deposition of the Titanyl-Oxide Moieties was not utilized in this Example 2.

[00090] FIG. 7 recites CFU/mL data for each of the three coating formulations, wherein each formulation did not include one or more titanium-oxide moieties. FIG. 8 recites Log Reduction data for the three formulations evaluated, wherein each formulation did not include one or more titanium-oxide moieties. FIG. 9 recites

Percent Reduction data for the three formulations utilized, wherein each formulation did not include one or more titanium-oxide moieties.

EXAMPLE 3

[00091] This Example 3 utilizes complete formulations ABS-G2015, AB-G2020, and ABS-G2030, where those coating formulations were disposed on stainless steel test coupons using the full procedure of Example 1. In one set of experiments, the formulations were disposed onto the test coupons using an electrostatic spray assembly. In another set of experiments, the formulations were disposed onto the test coupons using a non-electrostatic spray assembly.

[00092] FIG. 10, FIG. 11, and FIG. 12 recite anti-microbial efficacy data for the electrostatic spray embodiments. FIG. 13, FIG. 14, and FIG. 15 recite anti-microbial efficacy data for the non-electrostatic spray embodiments.

EXAMPLE 4

[00093] A study was conducted at the Glendale Memorial Hospital and Health Center in Glendale, CA (the "Glendale Memorial Hospital Study"). The Center has a 24 bed intensive care (ICU). The study was performed between May 10 and September 30, 2013. The Glendale Memorial Hospital Study was designed to assess the anti-microbial efficacy of coating composition ABS-G2015, described hereinabove, where that coating composition was applied using the complete method of Example 1 herein.

[00094] In the Glendale Memorial Hospital Study, the entire ICU was subjected to the two step spray regime described herein to treat all surfaces in each room including hard surfaces (beds, tray tables, bed rail, walls, etc.) and soft surfaces (drapes, cloth and vinyl covered chairs, etc.). More specifically, each surface was first electrostatically spray coated at room temperature using an aqueous composition formed by mixing Octadecylaminodimethyltri-hydroxysilylpropyl Ammonium Chloride (the "Silylated Quarternary Amine") at about 3.6 weight percent in water.

[00095] After about fifteen (15) minutes after the electrostatic spray coating using the aqueous Silylated Quarternary Amine, each surface was then electrostatically coated at room temperature using the Titanyl-Oxide Moieties described hereinabove.

[00096] The treated surfaces were maintained at room temperature during the spray deposition of the aqueous Silylated Quarternary Amine, and during the spray deposition of the Titanyl-Oxide Moieties. None of the treated surfaces were subjected to any elevated heat treatment wherein the treated surface was heated to a temperature greater than about room temperature after completion of the two step coating regime.

[00097] Ninety-five (95) specific sites in the ICU were selected for recurring sampling at weeks 1, 2, 4, 8, and 15, after the two step spraying regime. Those selected sites included bed rails, bed controls, tray tables, and walls above sinks. Samples were also collected from the two ICU nursing stations and waiting lobby including countertops, phones, computer keyboards, chair armrests and end tables. All movable items were inconspicuously tagged and coded over the course of the study so that the same objects could be sampled.

[00098] Areas of 100 cm² were sampled using a sponge stick containing Letheen broth (3M, St. Paul, MN) to neutralize any residual disinfectant. After collection the samples were immediately placed on ice packs and sent overnight to the University of Arizona for analysis by Professor Charles Gerba.

[00099] FIG. 1 hereto is a true and accurate copy of a first graph provided by the Manager, Infection Prevention, Dignity Health / Glendale Memorial Hospital & Health Center. Exhibit 1 graphically shows the number of hospital acquired *C-difficile* infections in the Glendale Memorial Hospital ICU from January 2012 through February 2014.

[000100] FIG 1 indicates that with the exception of September 2013, there were no hospital acquired *C-difficile* infections originating in the ICU during the period May 2013 through November 2013. Thus, FIG. 1 shows that there was a single hospital acquired *C-difficile* infection originating in the ICU during the six month period May 2013 through November 2013.

[000101] FIG. 1 further shows that, other than the six month period May 2013 through November 2013, there was no other 6 month period during the 25 months from January 2012 through February 2014 wherein only a single hospital acquired *C-difficile* infection originated in the ICU.

[000102] All surfaces in the ICU were treated as described hereinabove during the first week of May 2013 as part of the Glendale Memorial Hospital Study. FIG. 2 hereto is a true and accurate copy of a second graph provided by the Manager, Infection Prevention, Dignity Health / Glendale Memorial Hospital & Health Center. Exhibit 2 graphically shows the number of hospital acquired *C-difficile* infections at the Glendale Memorial Hospital (excluding ICU) from January 2012 through February 2014.

[000103] FIG. 2 indicates that, with the exception of April 2013, there were between 1 and 8 hospital acquired *C-difficile* infections every month during the 25 month period in hospital areas outside of the ICU. During the period May 2013 through November 2013, FIG. 2 shows that there were a total of 20 hospital acquired *C-difficile* infections originating outside of the ICU at the Glendale Memorial Hospital.

[000104] FIGs. 1 and 2 show that during the period May 2013 through November 2013, a single hospital acquired *C-difficile* infection originated in the ICU at the Glendale Memorial Hospital, and a total of 20 hospital acquired *C-difficile* infections originated outside of the ICU at the Glendale Memorial Hospital.

[000105] *Clostridium difficile* colitis or pseudomembranous colitis is colitis (inflammation of the large intestine) resulting from infection with *Clostridium difficile*, a type of spore-forming bacteria. It causes an infectious diarrhea called *C. difficile* diarrhea. Latent symptoms of *Clostridium difficile* infection (CDI) often mimic some flu-like symptoms and may mimic disease flare-ups in people with inflammatory bowel disease-associated colitis. *C. difficile* releases toxins that may cause bloating and diarrhea, with abdominal pain, which may become severe.

[000106] *C. difficile* is transmitted from person to person by the fecal-oral route. The organism forms heat-resistant spores that are not killed by alcohol-based hand cleansers or routine surface cleaning. Thus, these spores survive in clinical environments for long periods. Because of this, the bacteria may be cultured from almost any surface.


[000107] *Clostridium difficile* spores are extremely hardy, and can survive for long amounts of time in environments devoid of food. The spores are resistant to drying and heating, and also have resistance to many forms of antiseptic cleaners. *C. diff* can

also survive in spore form for as long as five months. The ability of *C. diff* to survive in this resistant form poses quite a challenge for hospitals.

[000108] Because *C. diff* forms heat-resistant spores that are not killed by alcohol-based hand cleansers or routine surface cleaning, the data of FIG.s 1 and 2 demonstrate that treatment of hard surfaces and soft surface in the Glendale Memorial Hospital ICU with ABS-G2015 necessarily reduced the occurrence of *C. diff* spores in that ICU. The data of FIG. 2 show that other hospital departments that were not treated with ABS-G2015 coating composition experienced a much greater level of hospital acquired *C. diff* infections, thereby corroborating the anti-microbial efficacy of the coating resulting from application of ABS-G2015 against *C. diff* spores.


[000109] In coating formulations ABS G2015, G2020, and G2030, depending on the stoichiometry of the mixture of triethanolamine and the organosilane, one or polymeric species are formed on a treated surface. In certain embodiments, and as shown in Reaction Scheme 2, triethanolamine 9 and organosilane 1 react to form a linear polymer 10, wherein n is greater than or equal to 1 and less than or equal to about 10.

REACTION SCHEME 2



[000110] In other embodiments, and as shown in Reaction Scheme 3, triethanolamine 9 and organosilane 1 react to form a branched polymer 11.


REACTION SCHEME 3



Wherein in Reaction Scheme 3, x is greater than or equal to 1 and less than or equal to about 10, and wherein y is greater than or equal to 1 and less than or equal to about 10.

[000111] In other embodiments, and as shown in Reaction Scheme 4, triethanolamine 9 and organosilane 1 react to form a cross-linked polymer 12.


REACTION SCHEME 4



Wherein in Reaction Scheme 4, x is greater than or equal to 1 and less than or equal to about 10, and wherein y is greater than or equal to 1 and less than or equal to about 10, and wherein z is greater than or equal to 1 and less than or equal to about 10.

[000112] In certain embodiments, Inventors' organosilane comprises tetraethylorthosilicate 13. In certain embodiments and as shown in Reaction Scheme 5 and depending on the stoichiometry of the starting materials 9 and 13, Inventors' cross-linked polymeric material 14 is formed by reaction of tetraethylorthosilicate 13 and triethanolamine 9. Reaction Scheme 5 illustrates a single Si atom having four (4) different polymer chains originating therefrom. Those skilled in the art will appreciate that Inventors' cross-linked polymer material 14 comprises a very high cross-link density.

REACTION SCHEME 5




Wherein in Reaction Scheme 5, a is greater than or equal to 1 and less than or equal to about 10, and wherein b is greater than or equal to 1 and less than or equal to about 10, and wherein c is greater than or equal to 1 and less than or equal to about 10, and wherein d is greater than or equal to 1 and less than or equal to about 10.

[000113] In certain embodiments and as shown in Reaction Scheme 6 and depending on the stoichiometry of the starting materials 15 and 13, Inventors' cross-

linked polymeric material 16 is formed by reaction of tetraethylorthosilicate 13 and diethanolamine 14. Reaction Scheme 6 illustrates a single Si atom having four (4) different polymer chains originating therefrom. Those skilled in the art will appreciate that Inventors' cross-linked polymer material 16 comprises a very high cross-link density.

REACTION SCHEME 6




Wherein in Reaction Scheme 6, a is greater than or equal to 1 and less than or equal to about 10, and wherein b is greater than or equal to 1 and less than or equal to about 10, and wherein c is greater than or equal to 1 and less than or equal to about 10, and wherein d is greater than or equal to 1 and less than or equal to about 10.

[000114] While the preferred embodiments of the present invention have been illustrated in detail, it should be apparent that modifications and adaptations to those embodiments may occur to one skilled in the art without departing from the scope of the present invention.

We Claim:

1. An antimicrobial coating formulation comprising:

(i) a silane having a structure (1),



(ii) peroxotitanium acid and peroxo-modified anatase sol; and

(iii) triethanolamine,

wherein R1, R2 and R3 are selected from the group consisting of -OH and -O-alkyl, and R4 is selected from the group consisting of -OH, -O-alkyl, -alkyl, γ -chloro-propyl, γ -amino-propyl, and quaternary ammonium salt-substituted alkyl.

2. The antimicrobial coating formulation of claim 1, wherein said silane is γ -chloropropylsilanetriol.

3. The antimicrobial coating formulation of claim 2, wherein said coating formulation, when disposed on a surface comprising Formica, exhibits a ≥ 1.50 log reduction in murine norovirus 4 hours after initial inoculation of murine norovirus on the surface.

4. The antimicrobial coating formulation of claim 2, wherein said coating formulation, when disposed on a surface comprising stainless steel, exhibits a 2.30 log reduction in murine norovirus 4 hours after initial inoculation of murine norovirus on the surface.

5. The antimicrobial coating formulation of claim 2, wherein said coating formulation, when disposed on a surface comprising stainless steel, exhibits a 2.58 log reduction in murine norovirus 6 hours after initial inoculation of murine norovirus on the surface.

6. The antimicrobial coating formulation of claim 1, wherein said silane is γ -aminopropylsilanetriol.

7. The antimicrobial coating formulation of claim 6, wherein said coating formulation, when disposed on a surface comprising Formica, exhibits a 1.00 log reduction in murine norovirus 4 hours after initial inoculation of murine norovirus on the surface.


8. The antimicrobial coating formulation of claim 6, wherein said coating formulation, when disposed on a surface comprising stainless steel, exhibits a ≥ 2.91 log reduction in murine norovirus 4 hours after initial inoculation of murine norovirus on the surface.

9. The antimicrobial coating formulation of claim 6, wherein said coating formulation, when disposed on a surface comprising stainless steel, exhibits a ≥ 2.91 log reduction in murine norovirus 6 hours after initial inoculation of murine norovirus on the surface.

10. A method of forming an antimicrobial coating on a surface, comprising:

disposing on said surface a first composition comprising:

(i) an organosilane having a structure,



(ii) triethanolamine; and


disposing on said surface a second composition comprising peroxotitanium acid and peroxo-modified anatase sol,

wherein R1, R2 and R3 are selected from the group consisting of -OH and -O-alkyl, and R4 is selected from the group consisting of -OH, -O-alkyl, -alkyl, γ -chloro-propyl, γ -amino-propyl, and quaternary ammonium salt-substituted alkyl.

11. The method of claim 10, wherein said silane is γ -chloropropylsilanetriol.

12. The method of claim 11, wherein said surface comprises Formica, and wherein said antimicrobial coating exhibits a ≥ 1.50 log reduction in murine norovirus 4 hours after initial inoculation of murine norovirus on the surface.
13. The method of claim 11, wherein said surface comprises stainless steel, and wherein said antimicrobial coating exhibits a 2.30 log reduction in murine norovirus 4 hours after initial inoculation of murine norovirus on the surface.
14. The method of claim 11, wherein said surface comprises stainless steel, and wherein said antimicrobial coating exhibits a 2.58 log reduction in murine norovirus 6 hours after initial inoculation of murine norovirus on the surface.
15. The method of claim 10, wherein said silane is γ -aminopropylsilanetriol.
16. The method of claim 15, wherein said surface comprises Formica, and wherein said antimicrobial coating exhibits a 1.00 log reduction in murine norovirus 4 hours after initial inoculation of murine norovirus on the surface.
17. The method of claim 15, wherein said surface comprises stainless steel, and wherein said antimicrobial coating exhibits a ≥ 2.91 log reduction in murine norovirus 4 hours after initial inoculation of murine norovirus on the surface.
18. The method of claim 15, wherein said surface comprises stainless steel, and wherein said antimicrobial coating exhibits a ≥ 2.91 log reduction in murine norovirus 6 hours after initial inoculation of murine norovirus on the surface.
19. The method of claim 10, wherein the silane and the triethanolamine react to form at least one of a linear, branched or cross-linked polymer on the surface.
20. The method of claim 10, wherein said silane is tetraethylorthosilicate.

ICU ACQUIRED C-DIFFICILE INFECTIONS
 GLENDALE MEMORIAL HOSPITAL ICU
 JANUARY 1, 2012 – FEBRUARY, 2014



*THE C-DIFF THAT OCCURRED ON SEPTEMBER 19, 2013 WAS MORE THAN 13 WEEKS AFTER THE APPLICATION ABS' APPLICATION WAS APPLIED MID-JUNE

FIG. 1

HOSPITAL ACQUIRED C-DIFFICILE INFECTIONS (EXCLUDING ICU)
 GLENDALE MEMORIAL HOSPITAL
 JANUARY 1, 2012 – FEBRUARY, 2014




FIG. 2

SURFACE TIME-KILL STUDY EVALUATING FOUR COATING FORMULATIONS AGAINST MURINE
NOROVIRUS: TIME ZERO DATA

Test Organism	Contact Time	Sample ID ^a	Viral Counts (TCID ₅₀ per mL)	Log ₁₀ Reduction	Percent Reduction
Murine norovirus	Time Zero	Formica - Ctrl	1.48E+07	N.A.	
		SS-Ctrl	6.76E+06		

^aSS: STAINLESS STEEL

FIG. 3

**SURFACE TIME-KILL STUDY EVALUATING FOUR COATING FORMULATIONS AGAINST MURINE
NOROVIRUS: 4 HOUR CONTACT TIME DATA**

Test Organism	Contact Time	Sample ID ^a	Viral Counts (TCID ₅₀ per mL)	Log ₁₀ Reduction	Percent Reduction
Murine norovirus	4 Hours	Ctrl (Formica)	1.00E+05	N.A.	
		Ctrl (SS)	6.76E+04		
		ABS-G2015 (SS)	6.76E+04	0.00	0%
		ABS-G2020 (Form)	≤ 3.16E+03	≥ 1.50	≥ 97%
		ABS-G2030 (Form)	6.76E+03	1.00	90%

^aSS: STAINLESS STEEL; SW: SURFACEWISE, FORM: FORMICA

^b"s": NO VIRAL CYTOPATHOLOGY OBSERVED BEYOND TOXIC LEVELS; THEREFORE TITER AT OR BELOW LIMIT
DETECTION

FIG. 4

SURFACE TIME-KILL STUDY EVALUATING TWO COATING FORMULATIONS AGAINST MURINE
NOROVIRUS: 4 HOUR CONTACT TIME DATA

Test Organism	Contact Time	Sample ID ^a	Viral Counts (TCID ₅₀ per ml)	Mean Viral Titer	Log ₁₀ Reduction Relative to Time Zero	Percent Reduction Relative to Time Zero	Log ₁₀ Reduction Relative to Timed Control	Percent Reduction Relative to Timed Control
Murine norovirus	4 Hours	SS-Control (Rep A)	6.76E+04	1.06E+05	1.47	97%	N.A	85.2%
		SS-Control (Rep B)	1.45E+05					
		ABS-G2020 (Rep A)	1.00E+04	1.57E+04	2.30	99.5%	0.83	
		ABS-G2020 (Rep B)	2.14E+04					
		ABS-G2030 (Rep A)	4.68E+03	≤3.92E+03	≥2.91	≥99.8%	≥1.43	
		ABS-G2030 (Rep A)	≤3.16E+03					

^aSS: STAINLESS STEEL

^b"s": NO VIRAL CYTOTOXICITY OBSERVED BEYOND TOXIC LEVELS; THEREFORE TITER AT OR BELOW LIMIT DETECTION

FIG. 5

SURFACE TIME-KILL STUDY EVALUATING TWO COATING FORMULATIONS AGAINST MURINE
NOROVIRUS: 6 HOUR CONTACT TIME DATA

Test Organism	Contact Time	Sample ID ^a	Viral Counts (TCID ₅₀ per ml)	Mean Viral Titer	Log ₁₀ Reduction Relative to Time Zero	Percent Reduction Relative to Time Zero	Log ₁₀ Reduction Relative to Timed Control	Percent Reduction Relative to Timed Control
Murine norovirus	6 Hours	SS-Control (Rep A)	3.16E+04	4.96E+04	1.80	98%	N.A.	N.A.
		SS-Control (Rep B)	6.76E+04					
		ABS-G2020 (Rep A)	1.00E+04	8.38E+03	2.58	99.7%	0.77	83.1%
		ABS-G2020 (Rep B)	6.76E+03					
		ABS-G2030 (Rep A)	4.68E+03	≤3.92E+03	≥2.91	≥99.8%	≥1.10	≥92.1%
		ABS-G2030 (Rep A)	≤3.16E+03					

^aSS: STAINLESS STEEL

^b"s": NO VIRAL CYTOTOXICITY OBSERVED BEYOND TOXIC LEVELS; THEREFORE TITER AT OR BELOW LIMIT DETECTION

FIG. 6

		CFU/mL									
		UNTREATED		ABS-G2015E - NO TiO2		ABS-G2020E - NO TiO2		ABS-G2030E - NO TiO2			
		A	B	A	B	A	B	A	B	A	B
0 HOUR	1.E+04	1.36E+07	9.70E+06	5.20E+06	1.13E+07					6.20E+06	
	1.E+05	1.60E+07	9.00E+06	4.00E+06	2.00E+06	1.50E+07	2.60E+07	4.00E+06	1.10E+07		
1 HOUR	1.E+01					0.00E+00	2.00E+03	0.00E+00	0.00E+00		
	1.E+02					0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+03					0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+04	1.30E+07	1.90E+06	9.10E+06	2.60E+06	0.00E+00	0.00E+00	0.00E+00	0.00E+00		
4 HOUR	1.E+05					0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+01			1.00E+02	3.00E+02	0.00E+00	1.00E+02	0.00E+00	0.00E+00		
	1.E+02				1.50E+04	0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+03					0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+04	3.70E+06	3.40E+06			0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+05					0.00E+00	0.00E+00	0.00E+00	0.00E+00		

FIG. 7

LOG REDUCTION

	ABS-G2015E - NO TiO2	ABS-G2020E - NO TiO2	ABS-G2030E - NO TiO2
0 HOUR	0.33	-0.23	0.23
1 HOUR	0.69	4.74	7.04
4 HOUR	2.84	5.55	6.55

FIG. 8

PERCENT REDUCTION

	ABS-G2015H	ABS-G2020H	ABS-G2030H
0 HOUR	53.42%	-69.77%	41.28%
1 HOUR	79.64%	100.00%	100.00%
4 HOUR	99.86%	100.00%	100.00%

FIG. 9

		CFU/mL									
		UNTREATED		ABS-G2015E		ABS-G2020E		ABS-G2030E			
		A	B	A	B	A	B	A	B		
0 HOUR	1.E+04	3.08E+07	4.80E+06			2.58E+07	1.66E+07				
	1.E+05	1.97E+08	2.30E+07	3.10E+07	4.10E+07	2.60E+07	3.40E+07	2.10E+07	2.00E+07		
1 HOUR	1.E+01					8.00E+02	2.00E+02	0.00E+00	0.00E+00		
	1.E+02					1.00E+03	0.00E+00	0.00E+00	0.00E+00		
	1.E+03					0.00E+00	0.00E+00	0.00E+00	0.00E+00		
4 HOUR	1.E+04	2.90E+06	6.40E+06	2.70E+06	3.80E+06	0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+01			1.63E+04		1.00E+02	0.00E+00	0.00E+00	0.00E+00		
	1.E+02			2.70E+04	6.20E+04	0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+03	2.70E+06	1.90E+05	7.00E+04	8.00E+04	0.00E+00	0.00E+00	0.00E+00	0.00E+00		
	1.E+04	1.30E+07	1.70E+06	2.00E+05	1.00E+05	0.00E+00	0.00E+00	0.00E+00	0.00E+00		

FIG. 10

LOG REDUCTION FROM TIME ZERO

	CONTROL	ABS-G2015E	ABS-62020E	ABS-G2030E
0 HOUR	N/A	0.25	0.40	0.49
1 HOUR	1.14	1.29	5.33	7.81
4 HOUR	1.16	2.91	6.71	7.81

FIG. 11

PERCENT REDUCTION FROM TIME ZERO

	CONTROL	ABS-G2015E	ABS-62020E	ABS-G2030E
0 HOUR	N/A	43/66%	59.94%	67.92%
1 HOUR	92.72%	94.91%	99.9995%	99.999998%
4 HOUR	93.12%	99.88%	99.999998%	99.999998%

FIG. 12

		CFU/mL							
		UNTREATED		ABS-G2015H		ABS-G2020H		ABS-G2030H	
		A	B	A	B	A	B	A	B
0 HOUR	1.E+04	6.00E+05	4.00E+05	5.00E+05	4.00E+05	1.00E+06	8.00E+05	1.00E+05	1.00E+05
	1.E+05	2.00E+06	2.00E+06	0.00E+00	0.00E+00	0.00E+00	1.00E+06	0.00E+00	0.00E+00
	1.E+01								
1 HOUR	1.E+02								
	1.E+03	9.00E+05	1.58E+06	9.10E+05	6.70E+05	2.00E+05	5.70E+05	0.00E+00	0.00E+00
	1.E+04	1.40E+06	1.70E+06	1.20E+06	3.00E+05	2.00E+05	9.00E+05	0.00E+00	0.00E+00
	1.E+05	0.00E+00	0.00E+00	4.00E+06	0.00E+00	0.00E+00	0.00E+00	0.00E+00	0.00E+00
	1.E+01								
4 HOUR	1.E+02								
	1.E+03	1.28E+06	4.80E+05	1.00E+04	4.00E+04	0.00E+00	0.00E+00	0.00E+00	0.00E+00
	1.E+04	8.00E+05	4.00E+05	0.00E+00	0.00E+00	0.00E+00	0.00E+00	0.00E+00	0.00E+00
	1.E+05	1.00E+06	1.00E+06	0.00E+00	0.00E+00	0.00E+00	0.00E+00	0.00E+00	0.00E+00

FIG. 13

LOG REDUCTION

	ABS-G2015H	ABS-G2020H	ABS-G2030H
0 HOUR	0.74	0.25	1.40
1 HOUR	-0.10	0.47	5.97
4 HOUR	2.0	5.92	5.92

FIG. 14

PERCENT REDUCTION

	ABS-G2015H	ABS-G2020H	ABS-G2030H
0 HOUR	82.00%	44.00%	96.00%
1 HOUR	-26.88%	66.49%	100.00%
4 HOUR	98.99%	100.00%	100.00%

FIG. 15